The human mucin MUC1 represents a well-established tumor marker in postoperative control of breast cancer patients and is currently being evaluated as a target in a variety of immunotherapeutic strategies including the development of efficient tumor vaccines (1) (2) (3) . The immunodominant epitope of MUC1 is a short peptide motif (DTR) within the mucincharacteristic variable number of tandem repeats (VNTR) 1 domain (4) . This domain consists of variable numbers of a tandemly repeated icosapeptide and varies in length according to a genetic polymorphism (5, 6) . The VNTR domain has been thought to be highly conserved with respect to the sequence of its peptide unit: PDTRPAPGSTAPPAHGVTSA (7) (8) (9) (10) . However, in a previous study, we were able to show that MUC1 tandem repeats of a human breast cancer cell line contain a series of sequence variations on the protein level (11) . The concerted replacement of Asp 2 -Thr 3 3 Glu-Ser was revealed at high incidence (in the order of 50% of the individual number of repeat units), and the single replacement of Pro 13 3 Ala was demonstrated to occur in approximately 30% of the repeats (11, 12) . Evidence for variations on the protein level was also revealed for MUC1 from individual human milk samples. 2 No nucleotide sequence information was reported to confirm these data on the DNA level and to exclude that some of the amino acid replacements were the result of posttranslational events, nor were these sporadic findings corroborated as related to the general structural features of human MUC1.
The occurrence of substitutions within the icosapeptide of the MUC1-VNTR domain is of high biomedical significance, particularly with regard to the concerted replacement of two adjacent positions in the immunodominant DTR motif. This motif is a preferred epitope in murine B-cell responses (4) and also in humans (2) and represents the primary target site for major histocompatibility complex-unrestricted cytotoxic T-cell responses in breast cancer patients (13) . Classical major histocompatibility complex-restricted responses to epitopes within the tandem repeat have been reported for many mouse strains (14) , and human cytotoxic T lymphocytes recognizing MUC1 peptide epitopes were also demonstrated (15), including major histocompatibility complex class II-dependent helper T-cell responses in vitro (16) . The results of these experimental studies have found application in a series of clinical studies. For example, anti-MUC1 peptide antibodies, like the DTR recognizing HMFG1, have been used to deliver high doses of yttrium to the peritoneum of ovarian cancer patients, and these initial trials were recently extended in a Phase III multicenter clinical trial (17) . Beyond antibody strategies, active specific immunotherapy based on MUC1 peptides has been performed in syngeneic and transgeneic mouse models, including naked DNA, viral vectors, peptides, and liposome encapsulation of peptides (17) . These attempts have led to a series of Phase I clinical studies using tandem repeat peptides of MUC1 in conjugation with a variety of carriers (17) .
The accumulating evidence from laboratories and clinics makes MUC1 tandem repeat peptide a primary immunotarget in anticancer strategies. Accordingly, structural aspects of the VNTR domain, which were not realized in previous sequencing studies of the gene (7) (8) (9) (10) , are of utmost importance for the design of efficient tumor vaccines.
MATERIALS AND METHODS
Samples-Blood samples were obtained from ten healthy unrelated individuals from the local blood bank. Breast tumor cell lines ZR75-1, MCF-7, T47D, and MDA-MB231, colorectal cell lines HT-29 and LS174T, and gastric cell lines KATO-III and AGS were obtained from American Type Culture Collection (Manassas, VA). Breast cell line MTSV1-7 was a gift from Dr. J. Taylor-Papadimitriou (Imperial Cancer Research Fund, London, United Kingdom), whereas pancreatic cell lines PANC1 and S2-013 were a gift from Dr. M. A. Hollingsworth (Eppley Institute, University of Nebraska, Omaha, NE). Fresh tumor tissue samples were obtained from the Department of Surgery (University of Cologne, Cologne, Germany), snap-frozen in liquid nitrogen, and kept frozen at Ϫ80°C.
Oligodeoxynucleotides-Two sets of oligodeoxynucleotides (flank-5ЈVNTR and flank-3ЈVNTR) were designed from sequences flanking the 5Ј end or the 3Ј end of the MUC1-VNTR domain. Repeat-specific primers were synthesized complementary to the sequence variations DNA Isolation-Genomic DNA from the blood samples was prepared using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Genomic DNA from cell lines and tissue samples was isolated using the Blood & Cell Culture DNA Kit (Qiagen).
MVR Analyses-The MVR-PCR analysis performed in this study was based on the method described by Jeffreys et al. (18, 19) . MVR analyses were performed by using a combination of MVR-specific primers and a primer fixed at the 5Ј or 3Ј sites in the DNA flanking the minisatellite to generate a ladder of PCR products starting from each variant repeat (20)) to each MVR-specific oligodeoxynucleotide. Variant specific primers were used at a low concentration (50 nM), whereas the driving amplification passed with high concentration (1 M) of the flanking primer of the VNTR domain and the N(20) primer itself. Samples (100 ng) of genomic DNA were amplified in 25-l reactions using the PCR buffer and enzyme system of GC-rich PCR Kit (Roche Diagnostics, Mannheim, Germany). Reaction mixtures were incubated for 3 min at 95°C, and then cycled for 40 s at 94°C, 1 min at 65°C and 4 min at 70°C (10 cycles) on a DNA Thermal Cycler (Hybaid MBS; Hybaid, Heidelberg, Germany), followed by a chase for 40 s at 94°C and 1 min at 65°C, with 4 min and 5 s increment/cycle at 70°C for 22 cycles, with a final extension of 10 min at 70°C. The MVR-PCR product ladders were separated by electrophoresis in 1.4% MoSieve agarose gels (10 cm in length; peqLab, Erlangen, Germany) using TAE buffer (40 mM Tris acetate and 1 mM EDTA) and stained with ethidium bromide. The MVR-PCR product ladder starting at the 5Ј or 3Ј end of the VNTR domain was read from the bottom of the gels. The first repeat unit at the 5Ј end of the domain was visible at approximately 650 bp, whereas the first repeat of the 3Ј end was isographic with polynucleotides of approximately 550 bp. MVR analyses were performed for the 5Ј and 3Ј regions of the MUC1-VNTR with the appropriately designed primers.
DNA Sequencing of PCR Products-Single bands within the PCR product ladders were cut from the agarose gel and purified using QiaEx Gel Extraction Kit (Qiagen). The cleared DNA samples were cloned into pGEM-T easy vector (Promega, Mannheim, Germany). After plasmid preparation using QIAprep Spin Miniprep Kit (Qiagen), DNA was sequenced using SP6 or T7 primer. The primer (10 pM) was annealed in the presence of 300 ng of plasmid DNA, 2 l of the Big Dye Cycle Sequencing Ready Reaction Kit (PerkinElmer Life Sciences), and double distilled H 2 O in a 10-l reaction mixture under the following conditions: 2 min at 96°C and 25 cycles of denaturation at 96°C for 10 s and annealing at 55°C for 4 min. The primer-annealed template was sequenced by the Big Dye terminator technique. After purification of the sequenced samples, electrophoresis was performed on an automated sequencing machine (ABI 377; PerkinElmer Life Sciences).
In this way, the sequencing of single bands within the PCR product ladder revealed the nucleotide sequence of 4 -6 repeat units. By sequencing of overlapping regions of the domain periphery, it was possible to obtain the complete nucleotide sequence from the first 11 repeats of the 5Ј end as well as of the first 13 repeat units of the 3Ј end of the VNTR domain. These sequences could be aligned with those obtained by analysis of the 5Ј-and 3Ј-flanking regions accessible after amplification of the entire VNTR domain by primers annealing in the terminal regions of exon 2. Sequence information corroborated the data from MVRA with respect to the identity and topology of each of the four sequence variations (Fig. 1, a and b) .
Length Polymorphism of Individual MUC1 VNTR Domains-The entire VNTR domain of MUC1 was amplified by PCR using a primer set flanking the VNTR domain (5Ј primer, 5Ј-TgAgTATgACCAgCAgCgTACTCTCCAgCC; 3Ј primer, 5Ј-ggAggTgAgAggAggTACCgTgCTATggTg). 200 ng of genomic DNA were amplified in 50-l reaction mixtures using the GC-rich PCR Kit (Roche Diagnostics). The temperature profile was as follows: once 3 min at 95°C, cycling for 30 s at 95°C, 4 min at 65°C (10 cycles) on a DNA Thermal Cycler (Biometra) followed by 30 s at 95°C, 4 min ϩ 5 s increment per each cycle at 65°C for 25 cycles with a final extension of 10 min at 72°C. The PCR products were separated by electrophoresis in 1% agarose gels and stained with ethidium bromide. In each sample, only one allele of the MUC1-VNTR domain was detectable. The number of repeat units that corresponded to the length of each individual allele was determined.
To verify the identity of the amplified MUC1-VNTR domain, the band was cut from the gel, and the DNA was purified (QiaEx Gel Extraction Kit; Qiagen) and cloned into pCR XL-Topo vector (Topo XL PCR Cloning Kit; Invitrogen, Groningen, the Netherlands). The insert Icosapeptide sequence: P D T R P A P G S T A P P A H G V T S A Repeats 5Ј-terminal of the VNTR-domain Repeats 3Ј-terminal of the VNTR-domain   1  2  3  4  5  6  7  8  9  10  11  13  12  11  10  9  8  7  6  5  4  3  2  1   01  2  3  2  4  1  1, 3  1  1  02 a Four amino acid replacements within the repeat peptide of MUC1 VNTR domains were analyzed on the DNA level by MVRA of individual genomic samples. Numbers 1-4 refer to the sequence variations: DT3 ES (GAC ACC3 GAG AGC), 1; P3 Q (CCA3 CAA), 2; P3 A (CCA3 GCA), 3; and P3 T (CCA3 ACA), 4. In repeats where nonvariant and variant sequences were detectable, the replacement number is given in italic.
b Individual genomic DNA was obtained from blood cells. 01-05, caucasians; 06, donor from Ghana; 07, donor from Tunisia; 08, donor from Iran; 09, donor from Morocco; and 10, donor from Indonesia. Tissue samples 11-16 were from cancer patients (no, normal; ca, carcinoma tissue) of pancreatic (pa), colorectal (co), or gastric (ga) origin.
was cut out using restriction enzyme EcoRI (New England BioLabs, Frankfurt a.M., Germany) and subcloned into pBluescript vector. After plasmid preparation (Qiagen Spin Miniprep Kit; Qiagen), DNA was sequenced using T3 or T7 primers (ABI 377; PerkinElmer Life Sciences).
Sequence data obtained were compared with the available nucleotide sequence of MUC1 (GenBank TM accession number M61170). At the 5Ј end of the VNTR domain, legible sequence started in nucleotide position 3601. In position 3821, the tandem repeat unit started, and it was possible to read the sequence of two peripheral repeat units. Sequence data at the 3Ј end of the domain started in nucleotide position 4181 and ended in position 3952 with the first degenerate repeat.
RESULTS
Four different sequence variations at the 5Ј-and 3Ј-terminal regions of the human MUC1 VNTR domain were analyzed by MVRA of 27 individual genomic DNA samples ( Table I ). The samples comprised normal tissues and cells (10 individual blood samples, 6 individual tissue samples adjacent to solid tumors, and 1 immortalized "normal" breast epithelial cell line) and a variety of cancer samples, including cell lines (2 gastric, 4 breast, 2 pancreatic, and 2 colorectal carcinoma cell lines) and solid tumors (2 pancreatic, 2 colorectal, and 2 gastric carcinomas). MVRA allowed for the identification of sequence variations in 11-13 terminal repeats from the 5Ј and 3Ј peripheries of the VNTR domain (Fig. 2, a and b) . Amplification products containing larger numbers of repeats were visible in the gels, but unequivocal assignments could not be made. Hence, the reported relative frequencies of the occurrence of variant sequences do not represent the entire domain. The incidence of variant repeats was higher in the 5Ј-terminal region than in the 3Ј-terminal regions. Considering 11 repeats at the 5Ј-terminal region, about 54% of the repeats contain at least one of the four sequence variations, on average (Table I ). Within 13 repeats at the 3Ј-terminal regions, the incidence is about 22%. It is obvious that some of the replacements, in particular, the DT3 ES substitution (sequence variation 1), occur in clusters (diads or triads), whereas others, like the P3 Q (sequence variation 2), P3 A (sequence variation 3), and P3 T (sequence variation 4), appear mainly in isolated repeats (Table I) .
To verify that the PCR band ladders from MVRA represented real sequence variations and not artifacts related to the primer design or PCR parameters, individual samples were analyzed by sequencing of the PCR products. By alignment of overlapping stretches (each corresponding to about 4 -6 repeats) with partial sequences obtained after amplification of the entire VNTR domain, complete sequence information was revealed for 11-13 repeats of the peripheral regions. Data on human breast cancer cell line T47D are presented in Fig. 1a to place the new sequence information into the context of previous reports (7) (8) (9) (10) and to define where the numbering of repeats starts at the 5Ј-and 3Ј-flanking regions of the VNTR domain. An additional sequence variation, which was extracted from sequence information on a partial DNA corresponding to a pentarepeat of human MUC1 (6), the concerted replacement of His-Gly (CAC GGT) by Val-Arg (GTC CGT), was also analyzed by MVRA. Specifically designed detection primers indicated the occurrence of this sequence variation in a few individual samples at low frequency and with highly variable repeat topology. However, sequence analyses of amplified PCR products revealed that the replacement did not exist and that the primers had stochastically annealed.
Sequence Variation 1: DT3 ES-The DT3 ES replacement (GAC ACC 3 GAG AGC) was found in all individual samples and represents the most frequent sequence variation within the peripheral regions of the VNTR domain (Table I) . Within the 5Ј-terminal regions, sequence variation 1 is localized primarily in repeats 9 and 10 ( Figs. 1 and 2) . Nearly 90% of the individual samples contain this sequence variation in a repeat cluster (two or three adjacent repeats). A similar pattern is revealed for the 3Ј-terminal region. All individual samples show a clustering from 2-4 adjacent repeats, with the highest frequency in repeats 11 and 12. No evidence for a random distribution of this replacement in the terminal VNTR regions Table I ). Accordingly, sequence variation 2 is restricted to repeats 2 and 6, whereas sequence variation 3 is confined mainly to repeats 5 and 10. With two exceptions, these variations were not detected in the 3Ј regions of the VNTR domain.
Sequence Variation 4: P3 T-The replacement of Pro

13
(CCA) with Thr (ACA), which was detected in this study by sequencing of PCR products, introduces a new potential glycosylation site into the repeat. It has not been described previously and seems to occur at low incidence. We could detect it exclusively in repeat 7 (5Ј region) ( Figs. 1 and 2 ; Table I ) with the exception of AGS cells, in which the first repeat of the 3Ј region was positive for this variant. Interestingly, analysis of the individual lengths of VNTR domains revealed that the occurrence of this variant was negatively associated with higher numbers of repeats (see below). A representative pattern of sequence variations is shown for the 5Ј and 3Ј regions in Fig. 3 . This pattern represents the majority of the individual samples and hence indicates the nonrandom distribution of sequence variations 1-4. No differences with respect to the topology or incidence of the sequence variations in tumor versus normal samples became evident. Also individuals of non-Caucasian race or different ethnic background were found to have the same set of replacements and, except for one individual, identical topology.
Analysis of Length Polymorphism-In 20 individual samples, MUC1 allele lengths ranged from 40 -52 tandemly repeated 60-bp units, whereas 60 -84 repeat units were found in 5 individual samples. In 18 of the 20 individuals, who have a smaller MUC1 allele, the substitution of P3 T (variant 4) in repeat 7 (5Ј peripheral region of the VNTR domain) was detectable. Only two individuals in the group did not show this replacement. By contrast, in all individual domains that exhibit more than 60 repeat units, a P3 T substitution was not identified in the respective repeat. The length determination of individual MUC1 alleles allowed us to estimate that 30 -60% of the VNTR domain was covered by MVRA.
DISCUSSION
The present study reveals for the first time insight into the nucleotide sequences of peripheral regions in the human MUC1 repeat domain. Although the primary structure of this mucin was elucidated about a decade ago, the entire domain of repetitive 60 bp comprising between 20 and 120 units was never subjected to a detailed sequence analysis. Repetitive DNA sequences, in particular, GC-rich polynucleotides, are difficult to amplify by standard PCR protocols. Accordingly, only partial information was previously accessible after amplification of the entire domain in exon 2 and sequence analysis of a few terminal repeats. The published repeat sequences from four independent groups (7-10) agree in the finding that the sequence of a common 60-bp unit does not show structural variation in different cellular specimens. In contrast to this, we recently obtained evidence on the protein level that individual domains can display considerable sequence variation reflected in a series of amino acid replacements in the 20-amino acid repeat (11) . The singular observation was demonstrated in the present study to represent a general phenomenon by showing that all individual MUC1 alleles under study do contain the same pattern of sequence variations with largely identical topology. The nearly constant localization of variant repeats in the peripheral regions indicates that they may have originated before multiple duplications generated a length polymorphic VNTR domain. The entire domain may have evolved accordingly as a recent expansion of sequence variable super-repeats. Sequence variability of repeat peptides seems to be a common feature of mucins because other members of the MUC family (MUC4) also exhibit multiple replacements in their repetitive units (20) .
Sequence variability raises the question of whether functional aspects of the mucin domain may be affected. However, because only one repeat in MUC1 was demonstrated to contain a further potential glycosylation site, whereas all other replacements preserve the site pattern, it can be assumed that the sequence context-dependent initiation of O-glycosylation should not be influenced. Semiquantitative Edman analyses of repeat peptides from tumor-associated MUC1 have confirmed this assumption and, in particular, did not reveal any indication of altered O-glycosylation of the variant ESR motif (11) . On the other hand, in vitro studies have recently shown that the replacement of Pro 13 with Ala in the repeat peptide AHG21 has a strong negative effect on initial O-glycosylation catalyzed by recombinant UDP-galNAc polypeptide N-acetylgalactosaminyl-transferase galNAc-T2 (21) .
Variations of the peptide sequence are expected to have a strong influence on the conformation and hence the antigenicity of the repeat unit. The most frequent variation, DT3 ES (sequence variation 1), could be of importance in the context of tumor vaccination because it may represent an alternative target for humoral or cellular immune responses. Some murine monoclonal antibodies with a specificity for the DTR motif are cross-reactive to this variant motif, whereas the majority are not. 3 This indicates that the ESR motif exhibits distinct struc-3 F.-G. Hanisch, unpublished observations. tural features, despite the fact that the amino acid replacements are conservative. To reveal the conformational features of the variant motif and its glycosylated derivatives, synthetic (glyco)peptides are currently analyzed by 800 MHz NMR spectroscopy. Knowledge of the structural features of the two alternative motifs (DTR versus ESR) in the repeat peptide of MUC1 is expected to aid the development of efficient tumor vaccines.
